SK1012004A3 - Použitie azitromycínu na výrobu liečiva na liečenie respiračných infekcií u človeka - Google Patents
Použitie azitromycínu na výrobu liečiva na liečenie respiračných infekcií u človeka Download PDFInfo
- Publication number
- SK1012004A3 SK1012004A3 SK101-2004A SK1012004A SK1012004A3 SK 1012004 A3 SK1012004 A3 SK 1012004A3 SK 1012004 A SK1012004 A SK 1012004A SK 1012004 A3 SK1012004 A3 SK 1012004A3
- Authority
- SK
- Slovakia
- Prior art keywords
- azithromycin
- dose
- medicament
- treatment
- range
- Prior art date
Links
- 229960004099 azithromycin Drugs 0.000 title claims abstract description 46
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 title claims abstract description 46
- 206010057190 Respiratory tract infections Diseases 0.000 title claims abstract description 17
- 239000003814 drug Substances 0.000 title claims description 15
- 238000004519 manufacturing process Methods 0.000 title claims description 8
- 230000037396 body weight Effects 0.000 claims description 13
- 208000022760 infectious otitis media Diseases 0.000 claims description 10
- 239000007788 liquid Substances 0.000 claims description 5
- 108090000623 proteins and genes Proteins 0.000 claims description 4
- 238000000034 method Methods 0.000 abstract description 8
- 208000015181 infectious disease Diseases 0.000 description 16
- 244000052769 pathogen Species 0.000 description 10
- 241000606768 Haemophilus influenzae Species 0.000 description 8
- 208000005141 Otitis Diseases 0.000 description 6
- 208000019258 ear infection Diseases 0.000 description 6
- 230000001154 acute effect Effects 0.000 description 5
- 230000001717 pathogenic effect Effects 0.000 description 5
- 241000699694 Gerbillinae Species 0.000 description 4
- 241000588655 Moraxella catarrhalis Species 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 206010033078 Otitis media Diseases 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 241000194032 Enterococcus faecalis Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000193996 Streptococcus pyogenes Species 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 210000000959 ear middle Anatomy 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000008029 eradication Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 210000003454 tympanic membrane Anatomy 0.000 description 2
- VQEMDSRIOVZAOM-UHFFFAOYSA-N 4-(4-methylsulfonylphenyl)-1,3-thiazol-2-amine Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=CSC(N)=N1 VQEMDSRIOVZAOM-UHFFFAOYSA-N 0.000 description 1
- 101150076489 B gene Proteins 0.000 description 1
- 206010008326 Cervicitis gonococcal Diseases 0.000 description 1
- 241000606153 Chlamydia trachomatis Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 1
- 229930006677 Erythromycin A Natural products 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010040007 Sense of oppression Diseases 0.000 description 1
- 201000010439 acute gonococcal cervicitis Diseases 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229960004924 azithromycin dihydrate Drugs 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 208000032625 disorder of ear Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 208000028320 gonococcal cervicitis Diseases 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000003120 macrolide antibiotic agent Substances 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000011125 single therapy Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 208000000143 urethritis Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31386701P | 2001-08-21 | 2001-08-21 | |
| PCT/IB2002/003076 WO2003018031A2 (en) | 2001-08-21 | 2002-07-31 | Single dose azithromycin for treating respiratory infections |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SK1012004A3 true SK1012004A3 (sk) | 2005-04-01 |
Family
ID=23217490
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SK101-2004A SK1012004A3 (sk) | 2001-08-21 | 2002-07-31 | Použitie azitromycínu na výrobu liečiva na liečenie respiračných infekcií u človeka |
Country Status (25)
| Country | Link |
|---|---|
| US (3) | US20030148964A1 (cs) |
| EP (1) | EP1418924A2 (cs) |
| JP (1) | JP2005501862A (cs) |
| KR (1) | KR20040032942A (cs) |
| AP (1) | AP1729A (cs) |
| BG (1) | BG108537A (cs) |
| BR (1) | BR0211830A (cs) |
| CA (1) | CA2458135A1 (cs) |
| CZ (1) | CZ2004232A3 (cs) |
| EA (1) | EA200400214A1 (cs) |
| EC (1) | ECSP044985A (cs) |
| GE (1) | GEP20063812B (cs) |
| HR (1) | HRP20040163A2 (cs) |
| HU (1) | HUP0401332A2 (cs) |
| IL (1) | IL159585A0 (cs) |
| IS (1) | IS7092A (cs) |
| MA (1) | MA27059A1 (cs) |
| MX (1) | MXPA04001605A (cs) |
| OA (1) | OA12845A (cs) |
| PL (1) | PL367888A1 (cs) |
| SK (1) | SK1012004A3 (cs) |
| TN (1) | TNSN04035A1 (cs) |
| WO (1) | WO2003018031A2 (cs) |
| YU (1) | YU8804A (cs) |
| ZA (1) | ZA200400804B (cs) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE421882T1 (de) * | 2003-07-24 | 2009-02-15 | Pliva Hrvatska D O O | Schnellösliches azithromycin in einzeldosisform |
| US6984403B2 (en) | 2003-12-04 | 2006-01-10 | Pfizer Inc. | Azithromycin dosage forms with reduced side effects |
| CA2547597A1 (en) | 2003-12-04 | 2005-06-16 | Pfizer Products Inc. | Multiparticulate compositions with improved stability |
| ES2600577T3 (es) | 2003-12-04 | 2017-02-09 | Bend Research, Inc. | Procedimiento de pulverización-solidificación que usa un extrusor para preparar composiciones en multipartículas de fármacos cristalinos |
| KR100844628B1 (ko) | 2003-12-04 | 2008-07-07 | 화이자 프로덕츠 인크. | 제약상 다입자의 제조 방법 |
| US20060116336A1 (en) * | 2004-03-17 | 2006-06-01 | American Pharmaceutical Partners, Inc. | Lyophilized azithromycin formulation |
| US7468428B2 (en) | 2004-03-17 | 2008-12-23 | App Pharmaceuticals, Llc | Lyophilized azithromycin formulation |
| EP3067047B1 (en) | 2005-12-08 | 2022-04-20 | Insmed Incorporated | Lipid-based compositions of antiinfectives for treating pulmonary infections |
| US9119783B2 (en) | 2007-05-07 | 2015-09-01 | Insmed Incorporated | Method of treating pulmonary disorders with liposomal amikacin formulations |
| US20090005326A1 (en) * | 2007-06-26 | 2009-01-01 | Idexx Laboratories, Inc. | Single dose roxithromycin |
| US20090197956A1 (en) * | 2008-02-04 | 2009-08-06 | Arbor Pharmaceuticals, Inc. | Treatment of acute otitis media with xylitol and n-acetylcysteine |
| WO2009114810A2 (en) * | 2008-03-14 | 2009-09-17 | The Florida International Uinversity Board Of Trustees | Use of ellagitannins as inhibitors of bacterial quorum sensing |
| CA2838188C (en) | 2011-06-04 | 2017-04-18 | Rochester General Hospital Research Institute | Compositions and methods related to p6 of haemophilus influenzae |
| US10124066B2 (en) | 2012-11-29 | 2018-11-13 | Insmed Incorporated | Stabilized vancomycin formulations |
| LT3466432T (lt) | 2014-05-15 | 2020-12-28 | Insmed Incorporated | Būdai, skirti plaučių netuberkuliozinėms mikobakterinėms infekcijoms gydyti |
| EP3773505B1 (en) | 2018-03-30 | 2026-04-29 | Insmed Incorporated | Methods for continuous manufacture of liposomal drug products |
| JP7449275B2 (ja) | 2018-05-02 | 2024-03-13 | インスメッド インコーポレイテッド | リポソーム薬物製剤の製造方法 |
| WO2021163451A1 (en) * | 2020-02-14 | 2021-08-19 | Asklepios Biopharmaceutical, Inc. | Method of treating gene therapy associated toxicity with antibiotics |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US53264A (en) * | 1866-03-20 | Improved ditching-machine | ||
| YU43116B (en) * | 1979-04-02 | 1989-04-30 | Pliva Pharm & Chem Works | Process for preparing 11-aza-4-o-cladinosyl-6-o-desosaminyl-15-ethyl-7,13,14-trihydroxy-3,5,7,9,12,14-hexamethyl-oxacyclopentadecane-2-one(11-aza-10-deox |
| SI8110592A8 (en) * | 1981-03-06 | 1996-06-30 | Pliva Pharm & Chem Works | Process for preparing of n-methyl-11-aza-10-deoxo-10-dihydroerythromycine a and derivatives thereof |
| US4474768A (en) * | 1982-07-19 | 1984-10-02 | Pfizer Inc. | N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor |
| WO1989000576A1 (en) * | 1987-07-09 | 1989-01-26 | Pfizer Inc. | Azithromycin dihydrate |
| WO1989002271A1 (en) * | 1987-09-10 | 1989-03-23 | Pfizer | Azithromycin and derivatives as antiprotozoal agents |
| YU45590A (sh) * | 1990-03-07 | 1992-07-20 | PLIVA FARMACEVTSKA, KEMIJSKA, PREHRAMBENA I KOZMETIČKA INDUSTRIJA s.p.o. | Novi kompleksi odnosno helati antibiotika s dvovalentnim i/ili trovalentnim metalima i postupci za njihovo dobijanje |
| TW271400B (cs) * | 1992-07-30 | 1996-03-01 | Pfizer | |
| US5686587A (en) * | 1993-05-19 | 1997-11-11 | Pfizer Inc. | Intermediate for azithromycin |
| US5605889A (en) * | 1994-04-29 | 1997-02-25 | Pfizer Inc. | Method of administering azithromycin |
| HUT77530A (hu) * | 1994-05-06 | 1998-05-28 | Pfizer Inc. | Azitromicint tartalmazó, szabályozott hatóanyag-felszabadítású dózisformák |
| HRP980189B1 (en) * | 1998-04-06 | 2004-04-30 | Pliva Pharm & Chem Works | Novel 15-membered lactams ketolides |
| US6239113B1 (en) * | 1999-03-31 | 2001-05-29 | Insite Vision, Incorporated | Topical treatment or prevention of ocular infections |
| US20040053264A1 (en) * | 2002-02-01 | 2004-03-18 | Park Sung Sup | Clinical panel assay using DNA chips |
-
2002
- 2002-07-31 CA CA002458135A patent/CA2458135A1/en not_active Abandoned
- 2002-07-31 EP EP02753170A patent/EP1418924A2/en not_active Withdrawn
- 2002-07-31 SK SK101-2004A patent/SK1012004A3/sk not_active Application Discontinuation
- 2002-07-31 KR KR10-2004-7002492A patent/KR20040032942A/ko not_active Ceased
- 2002-07-31 HR HR20040163A patent/HRP20040163A2/xx not_active Application Discontinuation
- 2002-07-31 YU YU8804A patent/YU8804A/sh unknown
- 2002-07-31 JP JP2003522549A patent/JP2005501862A/ja active Pending
- 2002-07-31 HU HU0401332A patent/HUP0401332A2/hu unknown
- 2002-07-31 IL IL15958502A patent/IL159585A0/xx unknown
- 2002-07-31 MX MXPA04001605A patent/MXPA04001605A/es active IP Right Grant
- 2002-07-31 GE GE5411A patent/GEP20063812B/en unknown
- 2002-07-31 WO PCT/IB2002/003076 patent/WO2003018031A2/en not_active Ceased
- 2002-07-31 OA OA1200400048A patent/OA12845A/en unknown
- 2002-07-31 CZ CZ2004232A patent/CZ2004232A3/cs unknown
- 2002-07-31 AP APAP/P/2004/002968A patent/AP1729A/en active
- 2002-07-31 EA EA200400214A patent/EA200400214A1/ru unknown
- 2002-07-31 PL PL02367888A patent/PL367888A1/xx not_active Application Discontinuation
- 2002-07-31 BR BR0211830-0A patent/BR0211830A/pt not_active IP Right Cessation
- 2002-08-21 US US10/224,903 patent/US20030148964A1/en not_active Abandoned
-
2003
- 2003-07-25 US US10/628,102 patent/US6987093B2/en not_active Expired - Fee Related
- 2003-12-23 IS IS7092A patent/IS7092A/is unknown
-
2004
- 2004-01-21 BG BG108537A patent/BG108537A/bg unknown
- 2004-01-30 ZA ZA200400804A patent/ZA200400804B/en unknown
- 2004-02-11 MA MA27523A patent/MA27059A1/fr unknown
- 2004-02-20 EC EC2004004985A patent/ECSP044985A/es unknown
- 2004-02-20 TN TNP2004000035A patent/TNSN04035A1/fr unknown
-
2005
- 2005-06-29 US US11/172,012 patent/US7067493B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| TNSN04035A1 (fr) | 2006-06-01 |
| BR0211830A (pt) | 2004-09-08 |
| US6987093B2 (en) | 2006-01-17 |
| CA2458135A1 (en) | 2003-03-06 |
| BG108537A (bg) | 2005-02-28 |
| ZA200400804B (en) | 2005-05-03 |
| MA27059A1 (fr) | 2004-12-20 |
| JP2005501862A (ja) | 2005-01-20 |
| US20050250712A1 (en) | 2005-11-10 |
| IL159585A0 (en) | 2004-06-01 |
| US20030148964A1 (en) | 2003-08-07 |
| MXPA04001605A (es) | 2004-07-08 |
| KR20040032942A (ko) | 2004-04-17 |
| CZ2004232A3 (cs) | 2005-10-12 |
| PL367888A1 (en) | 2005-03-07 |
| US20040023898A1 (en) | 2004-02-05 |
| IS7092A (is) | 2003-12-23 |
| AP1729A (en) | 2007-03-26 |
| US7067493B2 (en) | 2006-06-27 |
| HRP20040163A2 (en) | 2005-02-28 |
| AP2004002968A0 (en) | 2004-03-31 |
| YU8804A (sh) | 2006-08-17 |
| OA12845A (en) | 2006-09-15 |
| GEP20063812B (en) | 2006-05-10 |
| EA200400214A1 (ru) | 2004-06-24 |
| WO2003018031A3 (en) | 2003-10-02 |
| ECSP044985A (es) | 2004-04-28 |
| EP1418924A2 (en) | 2004-05-19 |
| WO2003018031A2 (en) | 2003-03-06 |
| HUP0401332A2 (hu) | 2004-11-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SK1012004A3 (sk) | Použitie azitromycínu na výrobu liečiva na liečenie respiračných infekcií u človeka | |
| Biondi et al. | Psychological stress, neuroimmunomodulation, and susceptibility to infectious diseases in animals and man: a review | |
| Imran et al. | Trends in the development of remdesivir based inventions against COVID-19 and other disorders: A patent review | |
| Henley et al. | Developmental ototoxicity | |
| Li et al. | A double-blind, randomized, placebo-controlled multicenter study of oseltamivir phosphate for treatment of influenza infection in China | |
| US20230111504A1 (en) | Coronaviridae infection and avermectins | |
| CN114504578A (zh) | 治疗、预防由病毒感染引起的相关疾病的药物及其用途 | |
| CN1342081A (zh) | 用于治疗由肉孢子虫、新孢子虫和弓形虫引起的疾病的三嗪酮化合物 | |
| US20200330487A1 (en) | Prevention and treatment of flu-type viral infections and related complications | |
| Channa et al. | Effect of ciprofoxacin on growing cartilage in albino rat pups | |
| US11090315B1 (en) | Prevention and treatment of flu-type viral infections and related complications | |
| AU2002313574A1 (en) | Single dose azithromycin for treating respiratory infections | |
| US20230030607A1 (en) | Novel oxygen pulse therapy method for treating COVID19 and viral, bacterial, fungal or parasitic respiratory and other diseases | |
| US20060210483A1 (en) | Non-systemic antibiotic formulations and related method of use and treatment of upper respiratory infections | |
| US20250120929A1 (en) | Method of treating virus-associated infection using acetaminophen | |
| Sataloff et al. | Very high-dose streptomycin labyrinthectomy | |
| WO2024129551A1 (en) | Solid dosage form of a small molecule antiviral and uses thereof | |
| Güris | Treatment and chemoprophylaxis | |
| WO2023052830A2 (en) | Prevention and treativient of flu-type viral infections and related complications | |
| US20060057133A1 (en) | Topical pathogenic-tissue-destroying liquid | |
| HK40114059A (zh) | α-1062用於治疗创伤性脑损伤 | |
| O'Horo | Azithromycin | |
| JP2024507417A (ja) | イヌパルボウイルス感染を治療するための組成物および方法 | |
| Selliah et al. | Pharmacokinetics of cationic liposome-encapsulated doxycycline in mice challenged with genital infection by Chlamydia trachomatis | |
| Singh et al. | Albendazole therapy in liver hydatidosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC9A | Refused patent application |